• 1.

    McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9. https://doi.org/10.1016/j.jalz.2011.03.005.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 2.

    Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29. https://doi.org/10.1016/S1474-4422(14)70090-0.

    Article 
    PubMed 

    Google Scholar
     

  • 3.

    Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62. https://doi.org/10.1016/j.jalz.2018.02.018.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 4.

    Lewczuk P, Riederer P, O’Bryant SE, Verbeek MM, Dubois B, Visser PJ, et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry. 2018;19:244–328. https://doi.org/10.1080/15622975.2017.1375556.

    Article 
    PubMed 

    Google Scholar
     

  • 5.

    Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Suárez-Calvet M, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative. Mol Psychiatry. 2021;26:429–42. https://doi.org/10.1038/s41380-020-00923-z.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 6.

    Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med. 2020;26:379–86. https://doi.org/10.1038/s41591-020-0755-1.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 7.

    de Wolf F, Ghanbari M, Licher S, McRae-McKee K, Gras L, Weverling GJ, et al. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study. Brain. 2020;143:1220–32. https://doi.org/10.1093/brain/awaa054.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 8.

    Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med. 2019;25:277–83. https://doi.org/10.1038/s41591-018-0304-3.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 9.

    Mielke MM, Hagen CE, Wennberg AMV, Airey DC, Savica R, Knopman DS, et al. Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic Study on Aging. JAMA Neurol. 2017;74:1073–80. https://doi.org/10.1001/jamaneurol.2017.1359.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 10.

    Zetterberg H, Bendlin BB. Biomarkers for Alzheimer’s disease-preparing for a new era of disease-modifying therapies. Mol Psychiatry. 2021;26:296–308. https://doi.org/10.1038/s41380-020-0721-9.

    Article 
    PubMed 

    Google Scholar
     

  • 11.

    Xiao X, Yeoh BS, Vijay-Kumar M. Lipocalin 2: an emerging player in iron homeostasis and inflammation. Annu Rev Nutr. 2017;37:103–30. https://doi.org/10.1146/annurev-nutr-071816-064559.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 12.

    Kim JH, Ko PW, Lee HW, Jeong JY, Lee MG, Kim JH, et al. Astrocyte-derived lipocalin-2 mediates hippocampal damage and cognitive deficits in experimental models of vascular dementia. Glia. 2017;65:1471–90. https://doi.org/10.1002/glia.23174.

    Article 
    PubMed 

    Google Scholar
     

  • 13.

    Llorens F, Hermann P, Villar-Piqué A, Diaz-Lucena D, Nägga K, Hansson O, et al. Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. Nat Commun. 2020;11:619. https://doi.org/10.1038/s41467-020-14373-2.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 14.

    Naudé PJW, Ramakers IHGB, van der Flier WM, Jiskoot LC, Reesink FE, Claassen JAHR, et al. Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer’s disease dementia. Neurobiol Aging. 2021;107:1–10. https://doi.org/10.1016/j.neurobiolaging.2021.07.001.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 15.

    Albert C, Zapf A, Haase M, Röver C, Pickering JW, Albert A, et al. Neutrophil gelatinase-associated lipocalin measured on clinical laboratory platforms for the prediction of acute kidney injury and the associated need for dialysis therapy: a systematic review and meta-analysis. Am J Kidney Dis. 2020;76:826–41.e1. https://doi.org/10.1053/j.ajkd.2020.05.015.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 16.

    Moschen AR, Adolph TE, Gerner RR, Wieser V, Tilg H. Lipocalin-2: a master mediator of intestinal and metabolic inflammation. Trends Endocrinol Metab. 2017;28:388–97. https://doi.org/10.1016/j.tem.2017.01.003.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 17.

    Song J, Kim OY. Perspectives in lipocalin-2: emerging biomarker for medical diagnosis and prognosis for Alzheimer’s disease. Clin Nutr Res. 2018;7:1–10. https://doi.org/10.7762/cnr.2018.7.1.1.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 18.

    das Neves SP, Taipa R, Marques F, Soares Costa P, Monárrez-Espino J, Palha JA, et al. Association between iron-related protein lipocalin 2 and cognitive impairment in cerebrospinal fluid and serum. Front Aging Neurosci. 2021;13:663837. https://doi.org/10.3389/fnagi.2021.663837.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 19.

    Choi J, Lee HW, Suk K. Increased plasma levels of lipocalin 2 in mild cognitive impairment. J Neurol Sci. 2011;305:28–33. https://doi.org/10.1016/j.jns.2011.03.023.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 20.

    Eruysal E, Ravdin L, Kamel H, Iadecola C, Ishii M. Plasma lipocalin-2 levels in the preclinical stage of Alzheimer’s disease. Alzheimers Dement (Amst). 2019;11:646–53. https://doi.org/10.1016/j.dadm.2019.07.004.

    Article 

    Google Scholar
     

  • 21.

    Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318–22. https://doi.org/10.1161/01.str.32.6.1318.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 22.

    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98. https://doi.org/10.1016/0022-3956(75)90026-6.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 23.

    Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539–47. https://doi.org/10.1212/WNL.0000000000002923.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 24.

    Schmidt C, Wolff M, Weitz M, Bartlau T, Korth C, Zerr I. Rapidly progressive Alzheimer disease. Arch Neurol. 2011;68:1124–30. https://doi.org/10.1001/archneurol.2011.189.30.

    Article 
    PubMed 

    Google Scholar
     

  • 25.

    Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9. https://doi.org/10.1016/j.jalz.2011.03.008.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 26.

    Skrobot OA, Black SE, Chen C, DeCarli C, Erkinjuntti T, Ford GA, et al. Progress toward standardized diagnosis of vascular cognitive impairment: guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement. 2018;14:280–92. https://doi.org/10.1016/j.jalz.2017.09.007.

    Article 
    PubMed 

    Google Scholar
     

  • 27.

    Hermann P, Appleby B, Brandel JP, Caughey B, Collins S, Geschwind MD, et al. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol. 2021;20:235–46. https://doi.org/10.1016/S1474-4422(20)30477-4.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 28.

    McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88–100. https://doi.org/10.1212/WNL.0000000000004058.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 29.

    Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–77. https://doi.org/10.1093/brain/awr179.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 30.

    Saddiki H, Fayosse A, Cognat E, et al. Age and the association between apolipoprotein E genotype and Alzheimer disease: a cerebrospinal fluid biomarker-based case-control study. PLoS Med. 2020;17:e1003289. https://doi.org/10.1371/journal.pmed.1003289.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 31.

    Bretz F, Hothorn T, Westfall P. Multiple comparisons using R. Boca Raton: CRC Press; 2010.


    Google Scholar
     

  • 32.

    Zerr I, Villar-Piqué A, Hermann P, Schmitz M, Varges D, Ferrer I, et al. Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. Alzheimers Res Ther. 2021;13:86. https://doi.org/10.1186/s13195-021-00815-6.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 33.

    Villar-Piqué A, Schmitz M, Hermann P, Goebel S, Bunck T, Varges D, et al. Plasma YKL-40 in the spectrum of neurodegenerative dementia. J Neuroinflammation. 2019;16:145. https://doi.org/10.1186/s12974-019-1531-3.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 34.

    Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, et al. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease. Brain. 2021:awab223. https://doi.org/10.1093/brain/awab223 Epub ahead of print.

  • 35.

    Ohara T, Hata J, Tanaka M, Honda T, Yamakage H, Yoshida D, et al. Serum soluble triggering receptor expressed on myeloid cells 2 as a biomarker for incident dementia: the Hisayama study. Ann Neurol. 2019;85:47–58. https://doi.org/10.1002/ana.25385.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 36.

    Naudé PJ, Nyakas C, Eiden LE, Ait-Ali D, van der Heide R, Engelborghs S, et al. Lipocalin 2: novel component of proinflammatory signaling in Alzheimer’s disease. FASEB J. 2012;26:2811–23. https://doi.org/10.1096/fj.11-202457.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 37.

    Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL, et al. The characterisation of subjective cognitive decline. Lancet Neurol. 2020;19:271–8. https://doi.org/10.1016/S1474-4422(19)30368-0.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 38.

    Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67. https://doi.org/10.1016/S1474-4422(13)70044-9.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 39.

    Zhang Y, Foncea R, Deis JA, Guo H, Bernlohr DA, Chen X. Lipocalin 2 expression and secretion is highly regulated by metabolic stress, cytokines, and nutrients in adipocytes. PLoS One. 2014;9:e96997. https://doi.org/10.1371/journal.pone.0096997.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 40.

    Itenov TS, Bangert K, Christensen PH, Jensen JU, Bestle MH, Procalcitonin and Survival Study (PASS)-study group. Serum and plasma neutrophil gelatinase associated lipocalin (NGAL) levels are not equivalent in patients admitted to intensive care. J Clin Lab Anal. 2014;28:163–7. https://doi.org/10.1002/jcla.21662.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 41.

    Lee S, Jha MK, Suk K. Lipocalin-2 in the inflammatory activation of brain astrocytes. Crit Rev Immunol. 2015;35:77–84. https://doi.org/10.1615/critrevimmunol.2015012127.

    Article 
    PubMed 

    Google Scholar
     

  • 42.

    Ranjbar Taklimie F, Gasterich N, Scheld M, Weiskirchen R, Beyer C, Clarner T, et al. Hypoxia induces astrocyte-derived lipocalin-2 in ischemic stroke. Int J Mol Sci. 2019;20:1271. https://doi.org/10.3390/ijms20061271.

    CAS 
    Article 
    PubMed Central 

    Google Scholar
     

  • 43.

    Wang G, Weng YC, Han X, Whaley JD, McCrae KR, Chou WH. Lipocalin-2 released in response to cerebral ischaemia mediates reperfusion injury in mice. J Cell Mol Med. 2015;19:1637–45. https://doi.org/10.1111/jcmm.12538.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 44.

    McAleese KE, Walker L, Graham S, Moya ELJ, Johnson M, Erskine D, et al. Parietal white matter lesions in Alzheimer’s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. Acta Neuropathol. 2017;134:459–73. https://doi.org/10.1007/s00401-017-1738-2.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 45.

    Mesquita SD, Ferreira AC, Falcao AM, Sousa JC, Oliveira TG, Correia-Neves M, et al. Lipocalin 2 modulates the cellular response to amyloid beta. Cell Death Differ. 2014;21:1588–99. https://doi.org/10.1038/cdd.2014.68.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 46.

    Dekens DW, Naudé PJW, Keijser JN, Boerema AS, De Deyn PP, Eisel ULM. Lipocalin 2 contributes to brain iron dysregulation but does not affect cognition, plaque load, and glial activation in the J20 Alzheimer mouse model. J Neuroinflammation. 2018;15:330. https://doi.org/10.1186/s12974-018-1372-5.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 47.

    Bawa KK, Krance SH, Herrmann N, Cogo-Moreira H, Ouk M, Yu D, et al. A peripheral neutrophil-related inflammatory factor predicts a decline in executive function in mild Alzheimer’s disease. J Neuroinflammation. 2020;17:84. https://doi.org/10.1186/s12974-020-01750-3.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 48.

    Ferreira AC, Dá Mesquita S, Sousa JC, Correia-Neves M, Sousa N, Palha JA, et al. From the periphery to the brain: Lipocalin-2, a friend or foe? Prog Neurobiol. 2015;131:120–36. https://doi.org/10.1016/j.pneurobio.2015.06.005.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Rights and permissions

    Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

    Disclaimer:

    This article is autogenerated using RSS feeds and has not been created or edited by OA JF.

    Click here for Source link (https://www.biomedcentral.com/)